This result suggests the clinical stage of COPD patients was associated with both HDAC2 expression and HDAC activity in PBMCs, which may be used as a novel biomarker to evaluate the severity of COPD. The gene discussed is HDAC2; the disease is chronic obstructive pulmonary disease.